Spiraprilat

Last updated

Spiraprilat
Spiraprilat.svg
Identifiers
  • (8S)-7-[(2S)-2-{[(1S)-1-Carboxy-3-phenylpropyl]amino}propanoyl]-1,4-dithia-7-azaspiro[4.4]nonane-8-carboxylic acid
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C20H26N2O5S2
Molar mass 438.56 g·mol−1
3D model (JSmol)
  • C[C@H](N[C@@H](CCc1ccccc1)C(=O)O)C(=O)N2CC3(C[C@H]2C(=O)O)SCCS3
  • InChI=1S/C20H26N2O5S2/c1-13(21-15(18(24)25)8-7-14-5-3-2-4-6-14)17(23)22-12-20(28-9-10-29-20)11-16(22)19(26)27/h2-6,13,15-16,21H,7-12H2,1H3,(H,24,25)(H,26,27)/t13-,15-,16-/m0/s1
  • Key:FMMDBLMCSDRUPA-BPUTZDHNSA-N

Spiraprilat is the active metabolite of spirapril. [1]

Related Research Articles

<span class="mw-page-title-main">Spirapril</span> Chemical compound

Spirapril, sold under the brand name Renormax among others, is an ACE inhibitor antihypertensive drug used to treat hypertension. It belongs to dicarboxy group of ACE inhibitors.

References

  1. ↑ Noble S, Sorkin EM (May 1995). "Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension". Drugs. 49 (5): 750–66. doi:10.2165/00003495-199549050-00008. PMID   7601014. S2CID   195691037.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.